

Claims:

1. The use of an EP4 receptor ligand in the manufacture of a medicament for the treatment of neuropathic pain.
2. The use of an EP4 receptor ligand in the manufacture of a medicament for the treatment of colon cancer.
3. The use of an EP4 receptor ligand according to claims 1 or 2 wherein the EP4 receptor ligand is combined with one or more further therapeutic agents.
4. The use of an EP4 receptor ligand according to claim 3 wherein the therapeutic agents may be any of: a COX-2 inhibitor, a 5-lipoxygenase inhibitor, low dose aspirin, NSAID's, a leukotriene receptor antagonist, DMARD's, an adenosine 1 agonist, a recombinant human TNF receptor fusion protein, a sodium channel antagonist, an NMDA antagonist, and a 5HT1 agonist.
5. A method of treating neuropathic pain in a mammal, including man, comprising administration of an effective amount of an EP4 receptor ligand.
6. A method of treating colon cancer in a mammal, including man, comprising administration of an effective amount of an EP4 receptor ligand.
7. A pharmaceutical composition comprising an EP4 receptor ligand for use in the treatment of neuropathic pain.
8. A pharmaceutical composition comprising an EP4 receptor ligand for use in the treatment of colon cancer.

9. A pharmaceutical composition comprising an EP4 receptor ligand and a COX-2 inhibitor, in combination with a pharmaceutically acceptable carrier.
- 5 10. The use of an EP4 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain.
11. The use of an EP4 receptor antagonist in the manufacture of a medicament for the treatment of colon cancer.
- 10 12. The use of an EP4 receptor antagonist according to claims 10 or 11 wherein the EP4 receptor antagonist is combined with one or more further therapeutic agents.
- 15 13. The use of an EP4 receptor antagonist according to claim 12 wherein the therapeutic agents may be any of: a COX-2 inhibitor, a 5-lipoxygenase inhibitor, low dose aspirin, NSAID's, a leukotriene receptor antagonist, DMARD's, an adenosine 1 agonist, a recombinant human TNF receptor fusion protein, a sodium channel antagonist, an NMDA antagonist, and a 5HT1 agonist.
- 20 14. A method of treating neuropathic pain in a mammal, including man, comprising administration of an effective amount of an EP4 receptor antagonist.
- 25 15. A method of treating colon cancer in a mammal, including man, comprising administration of an effective amount of an EP4 receptor antagonist.
- 30 16. A pharmaceutical composition comprising an EP4 receptor antagonist for use in the treatment of neuropathic pain.
- 35 17. A pharmaceutical composition comprising an EP4 receptor antagonist for use in the treatment of colon cancer.

18. A pharmaceutical composition comprising an EP4 receptor antagonist and a COX-2 inhibitor, in combination with a pharmaceutically acceptable carrier.

205020 24464001